epidemiologyЭпидемиология и ВакцинопрофилактикаEpidemiology and Vaccinal Prevention2073-30462619-0494«Numicom» LLC10.31631/2073-3046-2019-18-5-98-108epidemiology-837Research ArticleОБЗОРREVIEWВакцины для профилактики хантавирусных лихорадокVaccines for Prevention of Hantaviral Fevershttps://orcid.org/0000-0002-6416-2573СинюгинаА. А.SinyuginaA. A.

Синюгина Александра  Александровна –  научный сотрудник,  руководитель производственного направления.

поселение Московский, посёлок  Института полиомиелита, домовладение 8, корпус 1, Москва, 108819.

+7 (495)841-0173.

Aleksandra A. Sinyugina – researcher, head of production of Chumakov Federal scientific center of research and development of immune-and-biological products.

Premises 8, building 1, Village of Institute of Poliomyelitis, Settlement «Moskovskiy», Moscow, 108819.

+7 (495)841-0173.

asina.78@mail.ruhttps://orcid.org/0000-0001-6130-4145ИшмухаметовА. А.IshmukhametovA. A.

Ишмухаметов Айдар Айратович – генеральный  директор.

поселение  Московский, посёлок Института полиомиелита,   домовладение  8,  корпус  1,  Москва,108819.

+7 8(495)841-9002.

Aidar A. Ishmukhametov – general director of Chumakov Federal scientific center  of research  and  development of immune-and-biological products.

Premises 8, building 1, Village of Institute of Poliomyelitis, Settlement «Moskovskiy», Moscow, 108819.

+7 (495)841-9002.

ishmukhametov@chumakovs.suhttps://orcid.org/0000-0002-6656-1682ДзагуроваТ. К.DzagurovaТ. К.

Дзагурова Тамара Казбековна – заведующая лабораторией.

поселение Московский, посёлок Института полиомиелита, домовладение 8, корпус 1, Москва,108819.

+7 (495)841-094.

Tamara K. Dzagurova – head  of laboratory  of Chumakov Federal scientific center  of research  and  development of immune- and-biological products.

Premises 8, building 1, Village of Institute of Poliomyelitis, Settlement «Moskovskiy», Moscow, 108819. 

+7 (495)841-094.

centrglps@yandex.ruhttps://orcid.org/0000-0003-2198-7521БаловневаМ. В.BalovnevaМ. V.

Баловнева Мария Владимировна – ведущий научный сотрудник.

поселение  Московский, посёлок Института полиомиелита,   домовладение  8,  корпус  1,  Москва,108819.

+7 (495)841-094.

Maria V. Balovneva – leading researcher of Chumakov Federal scientific center of research and development of immune-and-biological products.

Premises 8, building 1, Village of Institute of Poliomyelitis, Settlement «Moskovskiy», Moscow, 108819.

+7 (495) 841-094.

mashasm@yandex.ruhttps://orcid.org/0000-0003-3642-6444ЕгороваМ. С.EgorovaМ. S.

Егорова Мария Сергеевна – старший научный сотрудник.

поселение  Московский, посёлок  Института полиомиелита, домовладение 8, корпус 1, Москва,108819.

+7 (495)841-094.

Maria S. Egorova – senior researcher  of Chumakov Federal scientific center of research and development of immune-and-biological products.

Premises 8, building  1, Village of Institute of Poliomyelitis, Settlement «Moskovskiy», Moscow, 108819.

+7 (495)841-094.

masha0787@mail.ruКурашоваС. С.KurashovaS. S.

Курашова Светлана Сергеевна – младший научный сотрудник.

поселение Московский, посёлок Института полиомиелита, домовладение 8, корпус 1, Москва,108819.

+7 (495)841-094.

Svetlana S. Kurashova – junior researcher  of Chumakov Federal scientific center  of research  and  development of immune-and-biological products.

Premises 8, building 1, Village of Institute of Poliomyelitis, Settlement «Moskovskiy», Moscow,  108819.

+7  (495)841-094.

svetlanak886@yandex.ruhttps://orcid.org/0000-0002-9038-7717КоротинаН. А.KorotinaN. A.

Коротина Наталья Александровна – научный сотрудник.

поселение  Московский, посёлок Института полиомиелита,  домовладение 8, корпус 1, Москва,108819.

+7 (495)841-094.

Natalya A. Korotina   – researcher  of Chumakov Federal scientific center  of research  and development of immune- and-biological products.

Premises 8, building 1, Village of Institute of Poliomyelitis, Settlement «Moskovskiy», Moscow, 108819.

+7 (495)841-094.

ryggik@gmail.comhttps://orcid.org/0000-0002-7463-1505ЛеоновичО. А.LeonovichO. A.

Леонович Оксана Александровна – старший научный сотрудник.

посёлок Института полиомиелита,   домовладение  8,  корпус  1,  Москва,108819.

+7 (495)841-094.

Oksana A. Leonovich  – senior  researcher  of Chumakov  Federal scientific center  of research  and  development of immune-and-biological products.

Premises 8, building 1, Village of Institute of Poliomyelitis, Settlement «Moskovskiy», Moscow, 108819.

+7 (495)841-094.

loa-73@mail.ruБалкинаА. С.BalkinaA. S.

поселение  Московский, посёлок Института полиомиелита,  домовладение 8, корпус 1, Москва,108819.

Premises 8, building 1, Village of Institute of Poliomyelitis, Settlement «Moskovskiy», Moscow, 108819. 

https://orcid.org/0000-0002-6829-1241ТкаченкоЕ. А.TkachenkoЕ. A.

Ткаченко Евгений  Александрович    – руководитель  научного  направления.

поселение  Московский, посёлок Института полиомиелита,  домовладение 8, корпус 1, Москва,108819.

+7 (495) 841-9035.

Evganiy A. Tkachenko – scientific supervisor  of Chumakov Federal scientific center of research and development of immune-and-biological products.

Premises 8, building 1, Village of Institute of Poliomyelitis, Settlement «Moskovskiy», Moscow, 108819.

+7 (495) 841-9035.

evgeniytkach@mail.ruФедеральный научный центр исследований и разработки иммунобиологических препаратов им. М.П. Чумакова РАНРоссияChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of SciencesRussian FederationФедеральный научный центр исследований и разработки иммунобиологических препаратов им. М.П. Чумакова РАН; Первый МГМУ им. И. М. Сеченова Минздрава России (Сеченовский Университет),РоссияChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences; Sechenov UniversityRussian Federation20190411201918598108Copyright © Синюгина А.А., Ишмухаметов А.А., Дзагурова Т.К., Баловнева М.В., Егорова М.С., Курашова С.С., Коротина Н.А., Леонович О.А., Балкина А.С., Ткаченко Е.А., 20192019Синюгина А.А., Ишмухаметов А.А., Дзагурова Т.К., Баловнева М.В., Егорова М.С., Курашова С.С., Коротина Н.А., Леонович О.А., Балкина А.С., Ткаченко Е.А.Sinyugina A.A., Ishmukhametov A.A., Dzagurova Т.К., Balovneva М.V., Egorova М.S., Kurashova S.S., Korotina N.A., Leonovich O.A., Balkina A.S., Tkachenko Е.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.epidemvac.ru/jour/article/view/837

Хантавирусы являются высоко патогенными для человека возбудителями хантавирусных лихорадок, включая  геморрагическую лихорадку с почечным синдромом, регистрируемую среди людей в странах евразийского континента и заболевание под названием «хантавирусный пульмональный синдром» – в странах Северной и Южной Америк. Совсем недавно распространение хантавирусных заболеваний было обнаружено и в Африке. До сих пор не существует лекарственных препаратов для специфической противовирусной терапии. Наиболее перспективным методом борьбы с хантавирусными лихорадками является специфическая профилактика, то есть вакцинация населения против хантавирусов, обусловливающих эндемичность разных территорий. В этом обзоре обобщены современные данные о существующих и разрабатываемых вакцинах против хантавирусных лихорадок. 

Hantaviruses are highly pathogenic causative agents of hantaviral fevers, including hemorrhagic fever with renal syndrome, registered among people in countries of the Eurasian continent and a disease  called «hantavirus  pulmonary  syndrome»  – in the countries of North and South America. More recently, the spread of hantaviral diseases has been detected in Africa. There are still no drugs for specific antiviral therapy. The most promising method of dealing with hantaviral fevers is specific prophylaxis, that is, vaccination of the population against hantaviruses, which determine the endemicity of different territories. This review summarizes current data on existing and developed vaccines against hantaviral fevers.

геморрагическая лихорадка с почечным синдромомхантавирусный пульмональный синдромвирус Puumalaвирус Dobrava-Belgradeвирус Hantaanвирус Seoulвирус Amurвирус Sin Nombreвирус Andeshemorhagic fever with renal syndromehantavirus pulmonary syndromevirus Puumalavirus Dobrava-Belgradevirus Hantaanvirus Seoulvirus Amurvirus Sin Nombrevirus AndesReferencesOya A. Japanese encephalitis vaccine: the vaccination. International Medical Foundation of Japan 1976; 69–72.Oya A. Japanese encephalitis vaccine: the vaccination. International Medical Foundation of Japan 1976; 69–72.Lee H.W., Ahn C.N. Development of a vaccine against hemorrhagic fever with renal syndrome. J. Korean Soc Virol. 1988. 18:143–148.Lee H.W., Ahn C.N. Development of a vaccine against hemorrhagic fever with renal syndrome. J. Korean Soc Virol. 1988. 18: 143–148.Lee H.W., Ahn C.N., Song J.W., et al. Field trial of an inactivated vaccine against hemorrhagic fever with renal syndrome in humans. Arch Virol. 1990. 1(Suppl 1): 35–47Lee H.W., Ahn C.N., Song J.W., et al. Field trial of an inactivated vaccine against hemorrhagic fever with renal syndrome in humans. Arch Virol. 1990. 1(Suppl 1): 35–47Yamanishi K, Tanishita O, Tamura M et al. Development of inactivated vaccine against virus causing hemorrhagic fever with renal syndrome. Vaccine. 1988. 6: 278–282.Yamanishi K, Tanishita O, Tamura M et al. Development of inactivated vaccine against virus causing hemorrhagic fever with renal syndrome. Vaccine. 1988. 6: 278–282.Ким Р., Ру Ч., Ким Г.М. с соавт. Специфическая профилактика ГЛПС в КНДР. Тезисы международного симпозиума по ГЛПС. Ленинград, СССР, 1991, C. 16–17Kim R., Ru Ch., Kim GM et al. Specific prevention of HFRS in the DPRK. Abstracts of the international symposium on HFRS. Leningrad, USSR, 1991:. 16–17. (In Russ.).Kim R, Ryu C, Kim G et al. Antibody formation and epidemiological preventive effect after vaccination with the inactivated vaccine against HFRS. In: Abstract of 2nd symposium on arboviruses in the Mediterranean countries, Dubrovnik, 1989. p 58.Kim R, Ryu C, Kim G et al. Antibody formation and epidemiological preventive effect after vaccination with the inactivated vaccine against HFRS. In: Abstract of 2nd symposium on arboviruses in the Mediterranean countries, Dubrovnik, 1989. p. 58.Kim R.J., Ru C, Kim G.M. The special prevention of HFRS in P.D.R of Korea. Chin Clin Exp Virol. 1991. 4: 487–492.Kim R.J., Ru C, Kim G.M. The special prevention of HFRS in P.D.R of Korea. Chin Clin Exp Virol. 1991. 4: 487–492.Sun Z, Yu Y, Wang W, Wang D. Studies on the purified inactivated epidemic hemorrhagic fever vaccine. Clinical trial of type 1 EHF vaccine in volunteers. In: Abstract of 2nd international conference on HFRS, Beijing, 1992. pp 109–110.Sun Z, Yu Y, Wang W, Wang D. Studies on the purified inactivated epidemic hemorrhagic fever vaccine. Clinical trial of type 1 EHF vaccine in volunteers. In: Abstract of 2nd international conference on HFRS, Beijing, 1992. pp. 109–110.Yu Y.X., Dong G.M., Yao X.J. et al. Comparative studies on the immunogenicity of different types of HFRS inactivated. Virol Sin. 1990. 1: 63–66.Yu Y.X., Dong G.M., Yao X.J. et al. Comparative studies on the immunogenicity of different types of HFRS inactivated. Virol Sin. 1990. 1: 63–66.Astakhova T., Slonova R., Minskaya L. et al. The elaboration of inactivated vaccine against HFRS. In: Abstract of 3rd international conference on HFRS and hantaviruses, Helsinki, 1995. p. 62.Astakhova T., Slonova R., Minskaya L. et al. The elaboration of inactivated vaccine against HFRS. In: Abstract of 3rd international conference on HFRS and hantaviruses, Helsinki, 1995. p. 62.Yu Y.X, Yao X.J, Dong G.M. et al. Antibody response of inactivated HFRS vaccine to homologous and heterologous types of the virus. Chin J Biol. 1990. 3: 14–16.Yu Y.X, Yao X.J, Dong G.M. et al. Antibody response of inactivated HFRS vaccine to homologous and heterologous types of the virus. Chin J Biol. 1990. 3: 14–16.Cho H.W., Howard CR. Antibody response in humans to an inactivated hantavirus vaccine (Hantavax). Vaccine. 1999 17: 2569–2575.Cho H.W., Howard CR. Antibody response in humans to an inactivated hantavirus vaccine (Hantavax). Vaccine. 1999 17: 2569–2575.Cho H.W., Howard C.R., Lee H.W. Review of an inactivated vaccine against hantaviruses. Intervirology. 2002. 45: 328–333.Cho H.W., Howard C.R., Lee H.W. Review of an inactivated vaccine against hantaviruses. Intervirology. 2002. 45: 328–333.Sohn Y.M., Rho H.O., Park M.S. et al. Primary humoral immuno responses to formalin inactivated hemorrhagic fever with renal syndrome vaccine (Hantavax): consideration of active immunization in South Korea. Yonsei Med J. 2001. 42: 278–284.Sohn Y.M., Rho H.O., Park M.S. et al. Primary humoral immuno responses to formalin inactivated hemorrhagic fever with renal syndrome vaccine (Hantavax): consideration of active immunization in South Korea. Yonsei Med J. 2001. 42: 278–284.Lee H.W., Chu Y.K., Woo Y.D. et al. Vaccine against haemorrhagic fever with renal syndrome. In: Saluzzo JF, Dodet В (eds) Factors in the emergence and control of rodent-borne diseases. Elsevier, Paris, 1999: 267–272.Lee H.W., Chu Y.K., Woo Y.D. et al. Vaccine against haemorrhagic fever with renal syndrome. In: Saluzzo JF, Dodet В (eds) Factors in the emergence and control of rodent-borne diseases. Elsevier, Paris, 1999: 267–272.Bozovic B, Lee H.W., Samardzic S. et al. Follow-up of immune response of the vaccines by Hantavax vaccine in endemic foci of hemorrhagic fever with renal syndrome in Yugoslavia. In: Abstract of 5th international conference on HFRS, HPS, and hantaviruses, Veyrier-du-Lac, France, 2001, p 235.Bozovic B, Lee H.W., Samardzic S. et al. Follow-up of immune response of the vaccines by Hantavax vaccine in endemic foci of hemorrhagic fever with renal syndrome in Yugoslavia. In: Abstract of 5th international conference on HFRS, HPS, and hantaviruses, Veyrier-du-Lac, France, 2001, p 235.de Carvalho N.C, Gonzalez Delia Valle M. et al. A Cross-protection against challenge with Puumala virus after immunization with nucleocapsid proteins from different hantaviruses. Virology. 2002. 76 (13): 6669–6677.de Carvalho N.C, Gonzalez Delia Valle M. et al. A Cross-protection against challenge with Puumala virus after immunization with nucleocapsid proteins from different hantaviruses. Virology. 2002. 76 (13): 6669–6677.Dargeviciute A, Brus S.K., Sasnauskas K. et al. Yeast-expressed Puumala hantavirus nucleocapsid protein induces protection in a bank vole model. Vaccine. 2002. 20 (29–30): 3523–3531.Dargeviciute A, Brus S.K., Sasnauskas K. et al. Yeast-expressed Puumala hantavirus nucleocapsid protein induces protection in a bank vole model. Vaccine. 2002. 20 (29–30): 3523–3531.Lee H.W., Chu Y.K., Cui Y.S. et al. Immune reaction of the vaccinated hamster with combination Hantaan-puumala vaccine. J Korean Soc Virol. 1997. 27: 39–47Lee H.W., Chu Y.K., Cui Y.S. et al. Immune reaction of the vaccinated hamster with combination Hantaan-puumala vaccine. J Korean Soc Virol. 1997. 27: 39–47Hwang Y.H., Kang M.S., Lim K.O., Lee S.M. Toxic epidermal necrolysis with ocular involvement following vaccination for hemorrhagic fever with renal syndrome. Yonsei Med. J. 2012. 53 (1): 228–230.Hwang Y.H., Kang M.S., Lim K.O., Lee S.M. Toxic epidermal necrolysis with ocular involvement following vaccination for hemorrhagic fever with renal syndrome. Yonsei Med. J. 2012. 53 (1): 228–230.Song G, Huang Y et al. Human trial of a bivalent inactivated GHKC vaccine against HFRS. In: Abstract of 2nd international conference on HFRS, Beijing, 1992. p. 103.Song G, Huang Y et al. Human trial of a bivalent inactivated GHKC vaccine against HFRS. In: Abstract of 2nd international conference on HFRS, Beijing, 1992. p. 103.Dong G., An Q., Zhihue Y., Wenxue L. Efficacy of a chicken embryo tissue culture inactivated HFRS vaccine used in a clinical trial. In: Abstract of 5th international conference on HFRS, HPS and hantaviruses 2001, France, p. 239.Dong G., An Q., Zhihue Y., Wenxue L. Efficacy of a chicken embryo tissue culture inactivated HFRS vaccine used in a clinical trial. In: Abstract of 5th international conference on HFRS, HPS and hantaviruses 2001, France, p. 239.Choi Y., Ahn C.J., Seong K.M. et al. Inactivated Hantaan virus vaccine derived from suspension culture of Vero cells. Vaccine. 2003. 21: 1867–1873.Choi Y., Ahn C.J., Seong K.M. et al. Inactivated Hantaan virus vaccine derived from suspension culture of Vero cells. Vaccine. 2003. 21: 1867–1873.Li D, Dong G. Vaccines against hantaviruses in China. In: Abstract of 5th international conference on HFRS, HPS, and hantaviruses, Veyrier-du-Lac, France, 2001. p. 121.Li D, Dong G. Vaccines against hantaviruses in China. In: Abstract of 5th international conference on HFRS, HPS, and hantaviruses, Veyrier-du-Lac, France, 2001. p. 121.Zhao T.G., Ying S et al. Effective appraisement of inactivated vaccine against HFRS prepared from Meriones unguiculatus and Alaetagulus pumillio kerr kidney culture. In: Abstract of 4th international conference on HFRS and hantaviruses, Atlanta, 1998. p. 104.Zhao T.G., Ying S et al. Effective appraisement of inactivated vaccine against HFRS prepared from Meriones unguiculatus and Alaetagulus pumillio kerr kidney culture. In: Abstract of 4th international conference on HFRS and hantaviruses, Atlanta, 1998. p. 104.Song G, Huang YC, Hang CS. Preliminary human trial of inactivated golden hamster kidney cell vaccine against HFRS. Vaccine. 1992. 10: 214–216.Song G, Huang YC, Hang CS. Preliminary human trial of inactivated golden hamster kidney cell vaccine against HFRS. Vaccine. 1992. 10:.214–216.Liu W.M., Song G, Zhang Q.F. Comparative studies on inactivating methods for production of inactivated cell culture vaccine against epidemic hemorrhagic fever. Chin J Virol. 1992. 3: 141–146.Liu W.M., Song G, Zhang Q.F. Comparative studies on inactivating methods for production of inactivated cell culture vaccine against epidemic hemorrhagic fever. Chin J Virol. 1992. 3: 141–146.Hang C.S., Xie Y.X., Wang S.W. Advances on development of purified bivalent vaccine against HFRS prepared on Vero cells. In: Abstract of 6th international conference on HFRS, HPS and hantaviruses, Seoul, 2004. p. 152.Hang C.S., Xie Y.X., Wang S.W. Advances on development of purified bivalent vaccine against HFRS prepared on Vero cells. In: Abstract of 6th international conference on HFRS, HPS and hantaviruses, Seoul, 2004. p. 152.Ткаченко Е.А., Дзагурова Т.К., Набатников П.А., Малкин А.Е., Коротина Н.А. и др. Разработка экспериментальной вакцины против геморрагической лихорадки с почечным синдромом. Медицинская вирусология. 2009. 26: 194–196.Tkachenko EA, Dzagurova TK, Nabatnikov PA et al. et al.. Development of an experimental vaccine against hemorrhagic fever with renal syndrome. Medical virology. 2009. 26: 194–196. (In Russ.).Ткаченко Е.А., Ишмухаметов А.А., Дзагурова Т.К. и др. Разработка экспериментально-промышленной технологии производства вакцины для профилактики геморрагической лихорадки с почечным синдромом. Ремедиум. 2015. 6: 47–53.Tkachenko EA, Ishmukhametov AA, Dzagurova TK et al. Development of an experimental-industrial technology for the production of a vaccine for the prevention of hemorrhagic fever with renal syndrome. Remedium. 2015. 6: 47–53. (In Russ.).Hao F.Y., Hui L.G., Zhao X.L. Efficacy test for inactivated epidemic hemorrhage fever vaccine using golden hamsters. Chin. J. Biol. 1996. 9: 69–72.Hao F.Y., Hui L.G., Zhao X.L. Efficacy test for inactivated epidemic hemorrhage fever vaccine using golden hamsters. Chin. J. Biol. 1996. 9: 69–72.Ren K., Lu Q.X., Song G. Serological efficacy of the inactivated golden hamster kidney cell vaccine against hemorrhagic fever with renal syndrome in human trial. Chin J Exp Clin Virol. 1996. 10: 10–15.Ren K., Lu Q.X., Song G. Serological efficacy of the inactivated golden hamster kidney cell vaccine against hemorrhagic fever with renal syndrome in human trial. Chin J Exp Clin Virol. 1996. 10: 10–15.Zhu Z.Y., Zeng R.F., Yu X.Y. Efficacy of inactivated EHF vaccine in clinical trial. Virol Sin. 1991. 6: 315–319.Zhu Z.Y., Zeng R.F., Yu X.Y. Efficacy of inactivated EHF vaccine in clinical trial. Virol Sin. 1991. 6: 315–319.Yu Y.X., Liu W.X., Nei Z.L. Neutralizing antibody response in humans immunized with Meriones gerbil kidney tissue culture inactivated HFRS vaccine assessed by two methods. Virol. Sin. 1992. 7: 176–180.Yu Y.X., Liu W.X., Nei Z.L. Neutralizing antibody response in humans immunized with Meriones gerbil kidney tissue culture inactivated HFRS vaccine assessed by two methods. Virol. Sin. 1992. 7: 176–180.Chen H.X., Wang N., Zhang Y. Evaluation of the efficacy of vaccines against HFRS and study on their antibody dependent immunization enhancement and immunological strategy. In: Abstract of 4th international conference on HFRS and hantaviruses, Atlanta, 1998. p. 87.Chen H.X., Wang N., Zhang Y. Evaluation of the efficacy of vaccines against HFRS and study on their antibody dependent immunization enhancement and immunological strategy. In: Abstract of 4th international conference on HFRS and hantaviruses, Atlanta, 1998. p. 87.Li D. Trends of HFRS epidemiology and the expanded program on immunization with hantavirus vaccines in China. In: Abstract of 8th international conference on HFRS HPS and hantavirus, Athens, 2010. p. 82.Li D. Trends of HFRS epidemiology and the expanded program on immunization with hantavirus vaccines in China. In: Abstract of 8th international conference on HFRS HPS and hantavirus, Athens, 2010. p. 82.Zhang Y.Z, Zou Y., Fu Z.F, Plyusnin A. Hantavirus infections in humans and animals, China. Emerg Infect Dis. 2010. 16 (8):1195–1203.Zhang Y.Z, Zou Y., Fu Z.F, Plyusnin A. Hantavirus infections in humans and animals, China. Emerg Infect Dis. 2010. 16 (8):1195–1203.Schmaljohn C.S. Vaccines for hantaviruses: progress and issues. Expert Rev Vaccines. 2012. 11 (5): 511–513.Schmaljohn C.S. Vaccines for hantaviruses: progress and issues. Expert Rev Vaccines. 2012. 11 (5): 511–513.Chu Y.K., Jennings G.B., Schmaljohn C.S. (1995) A vaccinia virus-vectored Hantaan virus vaccine protects hamsters from challenge with Hantaan and Seoul viruses but not Puumala virus. J. Virol. 69 (10): 6417–6423.Chu Y.K., Jennings G.B., Schmaljohn C.S. (1995) A vaccinia virus-vectored Hantaan virus vaccine protects hamsters from challenge with Hantaan and Seoul viruses but not Puumala virus. J. Virol. 69 (10): 6417–6423.Schmaljohn C. Vaccines for hantaviruses. Vaccine. 2009. 27: 61–64.Schmaljohn C. Vaccines for hantaviruses. Vaccine. 2009. 27: 61–64.Дзагурова Т.К., Ткаченко Е.А., Башкирцев В.Н., и др. Выделение и идентификация штаммов хантавирусов-возбудителей ГЛПС в европейской части России. Медицинская вирусология. 2008. 25: 142–150.Dzagurova TK, Tkachenko EA, Bashkirtsev VN, et al. Isolation and identification of strains of Hantavirus-pathogens of HFRS in the European part of Russia. Medical virology. 2008. 25: 142–150. (In Russ.).Klempa B, Tkachenko EA, Dzagurova TK et al. Hemorrhagic fever with renal syndrome caused by 2 lineages of Dobrava hantavirus, Russia. Emerg Infect Dis. 2008. 14: 617–625.Klempa B, Tkachenko EA, Dzagurova TK et al. Hemorrhagic fever with renal syndrome caused by 2 lineages of Dobrava hantavirus, Russia. Emerg Infect Dis. 2008. 14:617–625Дзагурова Т.К., Морозов В.Г., Юничева Ю.В. и др. Этиологическая роль генотипов вируса Добрава в структуре заболеваемости ГЛПС. Медицинская вирусология. 2009. 26: 165–167.Dzagurova TK, Morozov VG, Yunicheva YuV et al. The etiological role of the genotypes of the Dobrava virus in the morbidity structure of HFRS. Medical virology. 2009. 26: 165–167. (In Russ.)Дзагурова Т.К., Солопова О.Н., Свешников П.Г., Коротина Н.А. и др. Разработка иммуноферментной тест-системы на основе моноклональных антител для определения специфической активности вакцины против геморрагической лихорадки с почечным синдромом. Вопр. вирусол. 2013. 1: 40–44.Dzagurova TK, Solopova ON, Sveshnikov PG, Korotina N.A. et.al. Development of an ELISA test system based on monoclonal antibodies to determine the specific activity of a vaccine against hemorrhagic fever with renal syndrome. Vopr. virusol. 2013. 1: 40–44 (In Russ.)Бархалёва О.А., Воробьёва М.С., Ладыженская И.П., Ткаченко Е.А., Дзагурова Т.К. Вакцина против геморрагической лихорадки с почечным синдромом. Биопрепараты. 2011. 1: 27–30.Barkhaleva OA, Vorobyova MS, Ladyzhenskaya IP, Tkachenko EA, Dzagurova TK. Hemorrhagic fever vaccine with renal syndrome. Biological products. 2011. 1: 27–30. (In Russ.).Schmaljohn C., Hasty S., Dalrymple J. Preparation of candidate vaccinia-vectored vaccines for HFRS. Vaccine, 1992; 10: 10–13.Schmaljohn C., Hasty S., Dalrymple J. Preparation of candidate vaccinia-vectored vaccines for HFRS. Vaccine, 1992; 10: 10–13.Kamrud K., Nelle T., VanderZanden L. et al. Evaluation of naked DNA and alphavirus-based hantavirus vaccines. Abstracts of 4th Intern. Confer. on HFRS and Hantaviruses. Atlanta, USA, 1998, P. 95.Kamrud K., Nelle T., VanderZanden L. et al. Evaluation of naked DNA and alphavirus-based hantavirus vaccines. Abstracts of 4th Intern. Confer. on HFRS and Hantaviruses. Atlanta, USA, 1998, P. 95.Hooper J., Kamrud K., Elgh F. et al. Development and testing of DNA vaccines against hantaviruses. Am. J. of Trop. Med. and Hyg. 1998; 59 (Supplement 3): 124–125.48 Hooper J., Kamrud K., Elgh F. et al. Development and testing of DNA vaccines against hantaviruses. Am. J. of Trop. Med. and Hyg. 1998; 59 (Supplement 3): 124–125.Bharadwaj M., Lyons C., Wortman B., Hjelle B. Genetic immunization with Sin Nombre virus cDNAs induces T cell proliferative responses and antibodies in Balb/C mice. Am J of Trop. Med. and Hyg.. 1998; 59 (Supplement 3), P. 124.Bharadwaj M., Lyons C., Wortman B., Hjelle B. Genetic immunization with Sin Nombre virus cDNAs induces T cell proliferative responses and antibodies in Balb/C mice. Am J of Trop. Med. and Hyg.. 1998; 59 (Supplement 3), P. 124.Yoshimatsu K., Yoo Y.C., Yoshida R. Protective immunity of Hantaan virus nucleocapsid and envelope protein studied using baculovirus-expressed proteins. Arch. Virol. 1993; 130 (3–4): 365–376.Yoshimatsu K., Yoo Y.C., Yoshida R. Protective immunity of Hantaan virus nucleocapsid and envelope protein studied using baculovirus-expressed proteins. Arch. Virol. 1993; 130 (3–4): 365–376.Schmaljohn C.S., Chu Y.K., Schmaljohn A.L., Dalrymple J.M. Antigenic subunits of Hantaan virus expressed by baculovirus and vaccinia virus recombinants. Virology. 1990. 64 (7): 3162–3170.Schmaljohn C.S., Chu Y.K., Schmaljohn A.L., Dalrymple J.M. Antigenic subunits of Hantaan virus expressed by baculovirus and vaccinia virus recombinants. Virology. 1990. 64 (7): 3162–3170.McClain D.J., Summers P.L., Harrison S.A. et al. Clinical evaluation of a vaccinia-vectored Hantaan virus vaccine. J. Med. Virol. 2000; 60: 77–85.McClain D.J., Summers P.L., Harrison S.A. et al. Clinical evaluation of a vaccinia-vectored Hantaan virus vaccine. J. Med. Virol. 2000; 60: 77–85.Hammerbeck C.D., Wahl-Jensen V, Hooper J.W. Hantavirus. In: Barrett ADT, Stanberry L.R. (eds) Vaccines for biodefense and emerging and neglected diseases. Academic Press/Elsevier, London, 2009: 379–412.Hammerbeck C.D., Wahl-Jensen V, Hooper J.W. Hantavirus. In: Barrett ADT, Stanberry L.R. (eds) Vaccines for biodefense and emerging and neglected diseases. Academic Press/Elsevier, London, 2009: 379–412.Safronetz D, Hegde N.R., Ebihara H. et al. Adenovirus vectors expressing hantavirus proteins protect hamsters against lethal challenge with Andes virus. J Virol. 2009. 83: 7285–7295.Safronetz D, Hegde N.R., Ebihara H. et al. Adenovirus vectors expressing hantavirus proteins protect hamsters against lethal challenge with Andes virus. J Virol. 2009. 83: 7285–7295.Yuan Z.G., Li X.M., Mahmmod Y.S., Wang X.H. A single immunization with a recombinant canine adenovirus type 2 expressing the seoul virus Gn glycoprotein confers protective immunity against seoul virus in mice. Vaccine. 2009; 27: 5247–5251.Yuan Z.G., Li X.M., Mahmmod Y.S., Wang X.H. A single immunization with a recombinant canine adenovirus type 2 expressing the seoul virus Gn glycoprotein confers protective immunity against seoul virus in mice. Vaccine. 2009; 27: 5247–5251.Yuan Z.G., Luo S.J., Xu H.J. Generation of E3-deleted canine adenovirus type 2 expressing the Gc glycoprotein of Seoul virus by gene insertion or deletion of related terminal region sequences. J. Gen. Virol. 2010; 91: 1764–1771Yuan Z.G., Luo S.J., Xu H.J. Generation of E3-deleted canine adenovirus type 2 expressing the Gc glycoprotein of Seoul virus by gene insertion or deletion of related terminal region sequences. J. Gen. Virol. 2010; 91: 1764–1771Giese M. DNA-antiviral Vaccines: New developments and Approaches – a review. Virus Genes 1998; 17 (3): 219–32.Giese M. DNA-antiviral Vaccines: New developments and Approaches – a review. Virus Genes 1998; 17 (3): 219–32.Lai W.C., Bennett M. DNA vaccines. Crit. Rev.Immunol 1998; 18 (5): 449–84.Lai W.C., Bennett M. DNA vaccines. Crit. Rev.Immunol 1998; 18 (5): 449–84.Hooper J., Kamrud K., Elgh F., Custer D., Schmaljohn C. DNA vaccination with hantavirus M segment elicits neutralizing antibodies and protects Seoul virus infection. Virology. 1999; 255: 269–278.Hooper J., Kamrud K., Elgh F., Custer D., Schmaljohn C. DNA vaccination with hantavirus M segment elicits neutralizing antibodies and protects Seoul virus infection. Virology. 1999; 255: 269–278.Kamrud K., Hooper J., Elgh F., Schmaljohn C. Comparison of the protective efficacy of naked DNA, DNA-based Sindbis replicon, and packaged Sindbis replicon vectors expressing hantavirus structural genes in hamsters. Virology, 1999; 263: 209–219.Kamrud K., Hooper J., Elgh F., Schmaljohn C. Comparison of the protective efficacy of naked DNA, DNA-based Sindbis replicon, and packaged Sindbis replicon vectors expressing hantavirus structural genes in hamsters. Virology, 1999; 263: 209–219.Boudreau E., Sellers K., Rusnak J. et al. Phase 1 clinical study on the safety, tolerability and immunogenicity of Hantaan and Puumala DNA vaccines. In: Abstracts of the 8th international conference on HFRS HPS and hantavirus, Athens, 2010. p. 83.Boudreau E., Sellers K., Rusnak J. et al. Phase 1 clinical study on the safety, tolerability and immunogenicity of Hantaan and Puumala DNA vaccines. In: Abstracts of the 8th international conference on HFRS HPS and hantavirus, Athens, 2010. p. 83.Filatov F, Tkachenko E, Schmaljohn C, Hooper J et al. Immune response to aerosol delivery of the cloned hantavirus genes. In: Abstracts of 7th international conference on HFRS, HPS and hantaviruses, Buenos Aires, 2007. p. 187.Filatov F, Tkachenko E, Schmaljohn C, Hooper J et al. Immune response to aerosol delivery of the cloned hantavirus genes. In: Abstracts of 7th international conference on HFRS, HPS and hantaviruses, Buenos Aires, 2007. p. 187.Boudreau E.F., Josleyn M., Ullman D. A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for hemorrhagic fever with renal syndrome. Vaccine. 2012; 30: 1951–1958.Boudreau E.F., Josleyn M., Ullman D. A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for hemorrhagic fever with renal syndrome. Vaccine. 2012; 30: 1951–1958.Zhao C., Zhao Y.S, Wang S. Immunogenicity of a multiepitope DNA vaccine against hantavirus. Hum Vaccines Immunother. 2012; 8 (2): 208–215.Zhao C., Zhao Y.S, Wang S. Immunogenicity of a multiepitope DNA vaccine against hantavirus. Hum Vaccines Immunother. 2012; 8 (2): 208–215.Schmaljohn C.S, Spik K.W, Hooper J.W. DNA vaccines for HFRS: laboratory and clinical studies. Virus Res. 2014. 187: 91-6.Schmaljohn C.S, Spik K.W, Hooper J.W. DNA vaccines for HFRS: laboratory and clinical studies. Virus Res. 2014. 187:91-6.Kwilas S., Kishimori J.M., Josleyn M. et al. A Hantavirus Pulmonary Syndrome (HPS) DNA Vaccine Delivered Using a Spring-powered Jet Injector Elicits a Potent Neutralizing Antibody Response in Rabbits and Nonhuman Primates. Current Gene Therapy. 2014; 14: 200–210.Kwilas S., Kishimori J.M., Josleyn M. et al. A Hantavirus Pulmonary Syndrome (HPS) DNA Vaccine Delivered Using a Spring-powered Jet Injector Elicits a Potent Neutralizing Antibody Response in Rabbits and Nonhuman Primates. Current Gene Therapy. 2014; 14: 200–210.McCoy J.R., Mendoza J.M., Spik K.W. et al. Schmaljohn C.S., Sardesai N.Y., Broderick K.E. A multi-head intradermal electroporation device allows for tailored and increased dose DNA vaccine delivery to the skin. Hum Vaccin Immunother. 2015; 11 (3): 746–54.McCoy J.R., Mendoza J.M., Spik K.W. et al. Schmaljohn C.S., Sardesai N.Y., Broderick K.E. A multi-head intradermal electroporation device allows for tailored and increased dose DNA vaccine delivery to the skin. Hum Vaccin Immunother. 2015; 11 (3): 746–54.Hooper J.W., Moon J.E., Paolino K.M. et al. Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for haemorrhagic fever with renal syndrome delivered by intramuscular electroporation. Clin Microbiol Infect. 2014; 20 (5): 110–117.Hooper J.W., Moon J.E., Paolino K.M. et al. Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for haemorrhagic fever with renal syndrome delivered by intramuscular electroporation. Clin Microbiol Infect. 2014; 20 (5): 110–117.Cichutek K. DNA vaccines: development, standardization and regulation. Intervirology. 2000; 43: 331–8.Cichutek K. DNA vaccines: development, standardization and regulation. Intervirology. 2000; 43: 331–8.Haese N., Brocato R.L., Henderson T. et al. Antiviral Biologic Produced in DNA Vaccine/ Goose Platform Protects Hamsters Against Hantavirus Pulmonary Syndrome When Administered Post-exposure. PLOS Neglected Trop Dis. 2015; 1: 19.Haese N., Brocato R.L., Henderson T. et al. Antiviral Biologic Produced in DNA Vaccine/ Goose Platform Protects Hamsters Against Hantavirus Pulmonary Syndrome When Administered Post-exposure. PLOS Neglected Trop Dis. 2015; 1: 19.Hooper J.W., Brocato R.L., Kwilas S. A. et al. DNA vaccine–derived human IgG produced in transchromosomal bovines protect in lethal models of hantavirus pulmonary syndrome. Sci Transl Med. 2014. 26; 6 (264): 264–70.Hooper J.W., Brocato R.L., Kwilas S. A. et al. DNA vaccine–derived human IgG produced in transchromosomal bovines protect in lethal models of hantavirus pulmonary syndrome. Sci Transl Med. 2014. 26; 6 (264): 264–70.Kobak L., Raftery M.J., Voigt S. et al. Hantavirus-1 induced pathogenesis in mice with a humanized immune system. J. Gen. Virol. 2015. 96: 1258–63.Kobak L., Raftery M.J., Voigt S. et al. Hantavirus-1 induced pathogenesis in mice with a humanized immune system. J. Gen. Virol. 2015. 96: 1258–63.Hjelle B. Vaccines against hantaviruses. Expert Rev Vaccines. 2002. 1: 373–384.Hjelle B. Vaccines against hantaviruses. Expert Rev Vaccines. 2002. 1: 373–384.

The authors declare that there are no conflicts of interest present.